5-hydroxytryptophan has been researched along with Symptom Cluster in 21 studies
5-Hydroxytryptophan: The immediate precursor in the biosynthesis of SEROTONIN from tryptophan. It is used as an antiepileptic and antidepressant.
5-hydroxytryptophan : A tryptophan derivative that is tryptophan substituted by a hydroxy group at position 5.
| Excerpt | Relevance | Reference |
|---|---|---|
| "A quantitative evaluation of cerebellar ataxia, with an ataxia score (total, static, kinetic) and the measurement of objective values relating to the major symptoms, was used in 21 patients with hereditary ataxias treated for 12 months with high doses (16 mg/kg/day) of d-l-5-HTP, l-5-HTP or the combination d-l-5-HTP (16 mg/kg/day)--benserazide (6 mg/kg/day)." | 7.67 | Regression of cerebellar syndrome with long-term administration of 5-HTP or the combination 5-HTP-benserazide. ( Trouillas, P, 1984) |
| "A 14-year-old Saudi boy with cherry red spot-myoclonus syndrome and documented neuraminidase deficiency responded well to titrated doses of 5-hydroxytryptophan as an add-on treatment." | 7.67 | Successful treatment of cherry red spot-myoclonus syndrome with 5-hydroxytryptophan. ( Daif, AK; Gascon, G; Ozand, P; Wallenberg, B, 1988) |
| " L-5-hydroxytryptophan plus carbidopa was administered to eight patients with this disorder or other syndromes in which myoclonus is prominent." | 7.65 | L-5-hydroxytryptophan in treatment of several different syndromes in which myoclonus is prominent. ( Growdon, JH; Shahani, BT; Young, RR, 1976) |
| "Treatment with 5-hydroxytryptophan (4-6 mg/kg) and carbidopa (0." | 6.70 | A novel neurodevelopmental syndrome responsive to 5-hydroxytryptophan and carbidopa. ( Abeling, N; Bergmann, C; Blau, N; Häring, M; Häusler, M; Heimann, G; Ramaekers, VT; Senderek, J; Zerres, K, 2001) |
| "A quantitative evaluation of cerebellar ataxia, with an ataxia score (total, static, kinetic) and the measurement of objective values relating to the major symptoms, was used in 21 patients with hereditary ataxias treated for 12 months with high doses (16 mg/kg/day) of d-l-5-HTP, l-5-HTP or the combination d-l-5-HTP (16 mg/kg/day)--benserazide (6 mg/kg/day)." | 5.27 | Regression of cerebellar syndrome with long-term administration of 5-HTP or the combination 5-HTP-benserazide. ( Trouillas, P, 1984) |
| " The locomotor activity of the mice was evaluated after stimulation with D-amphetamine, and the behavioural serotonin syndrome and head twitches were investigated after L-5-hydroxytryptophan treatment." | 3.70 | D-amphetamine and L-5-hydroxytryptophan-induced behaviours in mice with genetically-altered expression of the alpha2C-adrenergic receptor subtype. ( Haapalinna, A; Kobilka, BK; Sallinen, J; Scheinin, M; Viitamaa, T, 1998) |
| "A quantitative evaluation of cerebellar ataxia, with an ataxia score (total, static, kinetic) and the measurement of objective values relating to the major symptoms, was used in 21 patients with hereditary ataxias treated for 12 months with high doses (16 mg/kg/day) of d-l-5-HTP, l-5-HTP or the combination d-l-5-HTP (16 mg/kg/day)--benserazide (6 mg/kg/day)." | 3.67 | Regression of cerebellar syndrome with long-term administration of 5-HTP or the combination 5-HTP-benserazide. ( Trouillas, P, 1984) |
| "A 14-year-old Saudi boy with cherry red spot-myoclonus syndrome and documented neuraminidase deficiency responded well to titrated doses of 5-hydroxytryptophan as an add-on treatment." | 3.67 | Successful treatment of cherry red spot-myoclonus syndrome with 5-hydroxytryptophan. ( Daif, AK; Gascon, G; Ozand, P; Wallenberg, B, 1988) |
| "This study evaluated the behavioral elements of three 5-HT-related syndromes (intraperitoneal 5-hydroxytryptophan after intracisternal 5,7-dihydroxytryptamine (DHT), p-chloroamphetamine (PCA), fenfluramine (FF), or combinations of drugs) scored from video-tapes and their relationship to locomotor activity (LMA) photocell recording, regional monoamine concentration and S-1 receptor binding." | 3.67 | Serotonin-lesion myoclonic syndromes. II. Analysis of individual syndrome elements, locomotor activity and behavioral correlations. ( Pranzatelli, MR; Snodgrass, SR, 1986) |
| " Coadministration of harmaline (but not harmine) and 5-hydroxytryptophan (tryptamine or m-chlorophenyl-piperazine) induced a lethal convulsive myoclonic syndrome which could not be evoked by either drug separately." | 3.67 | Harmala alkaloids and related beta-carbolines: a myoclonic model and antimyoclonic drugs. ( Pranzatelli, MR; Snodgrass, SR, 1987) |
| " L-5-hydroxytryptophan plus carbidopa was administered to eight patients with this disorder or other syndromes in which myoclonus is prominent." | 3.65 | L-5-hydroxytryptophan in treatment of several different syndromes in which myoclonus is prominent. ( Growdon, JH; Shahani, BT; Young, RR, 1976) |
| "Treatment with 5-hydroxytryptophan (4-6 mg/kg) and carbidopa (0." | 2.70 | A novel neurodevelopmental syndrome responsive to 5-hydroxytryptophan and carbidopa. ( Abeling, N; Bergmann, C; Blau, N; Häring, M; Häusler, M; Heimann, G; Ramaekers, VT; Senderek, J; Zerres, K, 2001) |
| "The serotonin syndrome is a potentially severe adverse drug interaction characterized by the triad of altered mental status, autonomic dysfunction, and neuromuscular abnormalities." | 2.39 | Serotonin syndrome. ( Martin, TG, 1996) |
| "PAK3-related intellectual disability is caused by mutations in the gene encoding the p21-activated kinase (PAK) protein." | 1.48 | Improvement of Self-Injury With Dopamine and Serotonin Replacement Therapy in a Patient With a Hemizygous PAK3 Mutation: A New Therapeutic Strategy for Neuropsychiatric Features of an Intellectual Disability Syndrome. ( Bartel, T; Blydt-Hansen, I; Connolly, MB; Horvath, GA; Race, S; Ross, CJ; Tarailo-Graovac, M; Van Allen, MI; van Karnebeek, CDM; Wasserman, WW, 2018) |
| "A quantitative evaluation of cerebellar ataxia, with an ataxia score (total, static, kinetic) and the measurement of objective values relating to the major symptoms, was used in 21 patients with hereditary ataxias treated for 12 months with high doses (16 mg/kg/day) of d-l-5-HTP, l-5-HTP or the combination d-l-5-HTP (16 mg/kg/day)--benserazide (6 mg/kg/day)." | 1.27 | Regression of cerebellar syndrome with long-term administration of 5-HTP or the combination 5-HTP-benserazide. ( Trouillas, P, 1984) |
| "Multiple forms of myoclonus (appendicular and truncal) and convulsions were dose-dependent drug effects." | 1.27 | Serotonin-lesion myoclonic syndromes. II. Analysis of individual syndrome elements, locomotor activity and behavioral correlations. ( Pranzatelli, MR; Snodgrass, SR, 1986) |
| "This new syndrome is called after the diviner Manto, quoted by Dante Alighieri in his 'Divina Commedia' (Inferno, XX, 52-56)." | 1.26 | Brainstem auditory evoked potentials in a case of 'Manto syndrome', or spasmodic torticollis with thoracic outlet syndrome. ( Disertori, B; Ducati, A; Pavani, M; Piazza, M, 1982) |
| "A case of spasmodic torticollis with thoracic outlet syndrome observed for over 18 months is presented and discussed." | 1.26 | Brainstem auditory evoked potentials in a case of 'Manto syndrome', or spasmodic torticollis with thoracic outlet syndrome. ( Disertori, B; Ducati, A; Pavani, M; Piazza, M, 1982) |
| "The syndrome was not seen after thioridazine (3-7 mg/kg)." | 1.26 | Acute dystonia as an idiosyncratic response to neuroleptics in baboons. ( Anlezark, GM; Marsden, CD; Meldrum, BS, 1977) |
| "In two patients with postanoxic action myoclonus, L-tryptophan or a monoamine oxidase inhibitor induced a moderate improvement, but L-5-hydroxytryptophan had greater therapeutic effect." | 1.26 | Beneficial effects of serotonin precursors in postanoxic action myoclonus. ( De Léan, J; Hornykiewicz, O; Richardson, JC, 1976) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 15 (71.43) | 18.7374 |
| 1990's | 2 (9.52) | 18.2507 |
| 2000's | 2 (9.52) | 29.6817 |
| 2010's | 2 (9.52) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Horvath, GA | 1 |
| Tarailo-Graovac, M | 1 |
| Bartel, T | 1 |
| Race, S | 1 |
| Van Allen, MI | 1 |
| Blydt-Hansen, I | 1 |
| Ross, CJ | 1 |
| Wasserman, WW | 1 |
| Connolly, MB | 1 |
| van Karnebeek, CDM | 1 |
| Ostabal Artigas, MI | 1 |
| Squires, LN | 1 |
| Talbot, KN | 1 |
| Rubakhin, SS | 1 |
| Sweedler, JV | 1 |
| Magnussen, I | 1 |
| Mondrup, K | 1 |
| Engbaek, F | 1 |
| Lademann, A | 1 |
| Olivarius, BD | 1 |
| Trouillas, P | 1 |
| Arushanian, EB | 1 |
| Dutov, AA | 1 |
| Rascol, A | 1 |
| Clanet, M | 1 |
| Montastruc, JL | 1 |
| Delage, W | 1 |
| Guiraud-Chaumeil, B | 1 |
| Disertori, B | 1 |
| Ducati, A | 1 |
| Piazza, M | 1 |
| Pavani, M | 1 |
| Martin, TG | 1 |
| Sallinen, J | 1 |
| Haapalinna, A | 1 |
| Viitamaa, T | 1 |
| Kobilka, BK | 1 |
| Scheinin, M | 1 |
| Ramaekers, VT | 1 |
| Senderek, J | 1 |
| Häusler, M | 1 |
| Häring, M | 1 |
| Abeling, N | 1 |
| Zerres, K | 1 |
| Bergmann, C | 1 |
| Heimann, G | 1 |
| Blau, N | 1 |
| Meldrum, BS | 1 |
| Anlezark, GM | 1 |
| Marsden, CD | 1 |
| De Léan, J | 1 |
| Richardson, JC | 1 |
| Hornykiewicz, O | 1 |
| Growdon, JH | 1 |
| Young, RR | 1 |
| Shahani, BT | 1 |
| Striano, S | 1 |
| Bilo, L | 1 |
| Meo, R | 1 |
| Gascon, G | 1 |
| Wallenberg, B | 1 |
| Daif, AK | 1 |
| Ozand, P | 1 |
| Pranzatelli, MR | 3 |
| Rubin, G | 1 |
| Snodgrass, SR | 3 |
| Nomura, Y | 1 |
| Segawa, M | 1 |
| Higurashi, M | 1 |
| Bhattacharya, SK | 1 |
| Sealy, WC | 1 |
3 reviews available for 5-hydroxytryptophan and Symptom Cluster
| Article | Year |
|---|---|
[Nigrostriatal system as a source of torsion extrapyramidal disorders (review)].
Topics: 5-Hydroxytryptophan; Acetylcholine; Animals; Basal Ganglia Diseases; Cats; Caudate Nucleus; Corpus S | 1980 |
Serotonin syndrome.
Topics: 5-Hydroxytryptophan; Diagnosis, Differential; Dose-Response Relationship, Drug; Humans; Neuroleptic | 1996 |
Paraneoplastic syndromes resulting from elaboration of ectopic hormones, antigens and bizarre toxins.
Topics: 5-Hydroxytryptophan; Acanthosis Nigricans; Carcinoid Tumor; Carotid Body Tumor; Catecholamines; Cush | 1972 |
1 trial available for 5-hydroxytryptophan and Symptom Cluster
| Article | Year |
|---|---|
A novel neurodevelopmental syndrome responsive to 5-hydroxytryptophan and carbidopa.
Topics: 5-Hydroxytryptophan; Abnormalities, Multiple; Carbidopa; Child; Child, Preschool; Developmental Disa | 2001 |
17 other studies available for 5-hydroxytryptophan and Symptom Cluster
| Article | Year |
|---|---|
Improvement of Self-Injury With Dopamine and Serotonin Replacement Therapy in a Patient With a Hemizygous PAK3 Mutation: A New Therapeutic Strategy for Neuropsychiatric Features of an Intellectual Disability Syndrome.
Topics: 5-Hydroxytryptophan; Adolescent; Brain; Carbidopa; Dopamine; Drug Combinations; Humans; Intellectual | 2018 |
[Serotoninergic syndrome due to interaction between linezolid and 5-hydroxytryptophan].
Topics: 5-Hydroxytryptophan; Anti-Bacterial Agents; Antidepressive Agents, Second-Generation; Depression; Di | 2015 |
Serotonin catabolism in the central and enteric nervous systems of rats upon induction of serotonin syndrome.
Topics: 5-Hydroxytryptophan; Animals; Behavior, Animal; Brain; Central Nervous System; Disease Models, Anima | 2007 |
Treatment of myoclonic syndromes with paroxetine alone or combined with 5-HTP.
Topics: 5-Hydroxytryptophan; Adult; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Myoclonus; | 1982 |
Regression of cerebellar syndrome with long-term administration of 5-HTP or the combination 5-HTP-benserazide.
Topics: 5-Hydroxytryptophan; Benserazide; Cerebellar Ataxia; Dopamine; Drug Therapy, Combination; Friedreich | 1984 |
L5H tryptophan in the cerebellar syndrome treatment.
Topics: 5-Hydroxytryptophan; Cerebellar Diseases; Humans; Syndrome; Time Factors | 1981 |
Brainstem auditory evoked potentials in a case of 'Manto syndrome', or spasmodic torticollis with thoracic outlet syndrome.
Topics: 5-Hydroxytryptophan; Adult; Brain Stem; Evoked Potentials, Auditory; Female; Humans; Muscle Spastici | 1982 |
D-amphetamine and L-5-hydroxytryptophan-induced behaviours in mice with genetically-altered expression of the alpha2C-adrenergic receptor subtype.
Topics: 5-Hydroxytryptophan; Adrenergic alpha-Agonists; Animals; Crosses, Genetic; Dextroamphetamine; Female | 1998 |
Acute dystonia as an idiosyncratic response to neuroleptics in baboons.
Topics: 5-Hydroxytryptophan; Acute Disease; Animals; Apomorphine; Corpus Striatum; Disease Models, Animal; H | 1977 |
Beneficial effects of serotonin precursors in postanoxic action myoclonus.
Topics: 5-Hydroxytryptophan; Aged; Carbidopa; Female; Humans; Hydroxyindoleacetic Acid; Hypoxia; Levodopa; M | 1976 |
L-5-hydroxytryptophan in treatment of several different syndromes in which myoclonus is prominent.
Topics: 5-Hydroxytryptophan; Adolescent; Adult; Carbidopa; Child, Preschool; Drug Evaluation; Female; Humans | 1976 |
An unusual case of Kleine-Levin syndrome associated with sleep terrors.
Topics: 5-Hydroxytryptophan; Adult; Craniocerebral Trauma; Electroencephalography; Humans; Male; Sleep Wake | 1986 |
Successful treatment of cherry red spot-myoclonus syndrome with 5-hydroxytryptophan.
Topics: 5-Hydroxytryptophan; Adolescent; Female; Humans; Male; Myoclonus; Neuraminidase; Pedigree; Syndrome | 1988 |
Serotonin-lesion myoclonic syndromes. I. Neurochemical profile and S-1 receptor binding.
Topics: 5-Hydroxytryptophan; 5,7-Dihydroxytryptamine; Amphetamines; Animals; Biogenic Amines; Brain; Brain C | 1986 |
Serotonin-lesion myoclonic syndromes. II. Analysis of individual syndrome elements, locomotor activity and behavioral correlations.
Topics: 5-Hydroxytryptophan; 5,7-Dihydroxytryptamine; Amphetamines; Animals; Dihydroxytryptamines; Drug Inte | 1986 |
Harmala alkaloids and related beta-carbolines: a myoclonic model and antimyoclonic drugs.
Topics: 5-Hydroxytryptophan; Alkaloids; Animals; Carbolines; Male; Motor Activity; Myoclonus; Rats; Rats, In | 1987 |
Rett syndrome--an early catecholamine and indolamine deficient disorder?
Topics: 5-Hydroxytryptophan; Adolescent; Basal Ganglia; Catecholamines; Child; Child, Preschool; Droxidopa; | 1985 |